# Nalagenetics Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nalagenetics-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.nalagenetics.com
- Total disclosed funding: $15M
- Latest round: Series B (Mar 22, 2022)
- Investors on record: 13

## About

Nalagenetics Pte. Ltd. specializes in genetic testing solutions aimed at providing personalized health insights for individuals, helping them manage their health risks and wellness more effectively.Founded in 2016 in Singapore, Nalagenetics Pte. Ltd. focuses on personalized genetic testing. The company has conducted 4 deals, with the most recent funding round being a Series B completed in March 2022, raising USD 12.62 mn. The founders, Alexander Lezhava and Jianjun Liu, have established a company that reflects the genetic diversity of the Southeast Asian population with a current valuation of USD 33.30 mn.Nalagenetics offers a comprehensive suite of genetic testing solutions designed to empower individuals with personalized health insights. Their core products include MammoReady™, a test for assessing breast cancer risk; NutriReady™, which tailors nutrition based on genetic predispositions; RxReady™, which personalizes medication plans to avoid adverse reactions; and LifeReady™, focusing on enhancing overall wellness through lifestyle adjustments. These products cater to high-risk individuals and families planning for healthier futures, addressing health concerns related to nutrition, cancer risk, and cardiovascular health through non-invasive DNA testing methods. The company employs advanced technologies, including microarray and qPCR, to ensure accurate and relevant insights for the Southeast Asian population.In 2021, Nalagenetics reported a revenue of USD 462.70 mn, with an EBITDA of USD -1,068,133.Following the Series B funding round in March 2022, Nalagenetics plans to expand its operations into Malaysia and other Southeast Asian countries. The funding will be utilized for hiring additional bioinformatics professionals, software engineers, and geneticists to support this expansion. Upcoming product launches and enhancements are also part of the growth strategy, although specific details on release dates have not been disclosed.

## Funding rounds

- Series B, Mar 22, 2022, $13M — Vulcan, East Ventures, Integra Partners, GDP Venture, Intudo Ventures, Agaeti Venture Capital, SGInnovate, AC Ventures, Brama One Ventures, Looking Glass Capital, Agency for Science, Technology and Research, Dexa International
- Series A, Jun 10, 2020, $1M — East Ventures, Mensa Group, Intudo Ventures, Agency for Science, Technology and Research
- Seed, Nov 1, 2018, $1M — East Ventures, Intudo Ventures

## Investors

- East Ventures (https://capitalatlas.ai/funds/east-ventures) — Seed, Series A, Series B
- Intudo Ventures (https://capitalatlas.ai/funds/intudo-ventures) — Seed, Series A, Series B
- Mensa Group — Series A
- Agency for Science, Technology and Research — Series A, Series B
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series B
- Integra Partners (https://capitalatlas.ai/funds/integra-partners) — Series B
- GDP Venture (https://capitalatlas.ai/funds/gdp-venture) — Series B
- Agaeti Venture Capital (https://capitalatlas.ai/funds/agaeti-venture-capital) — Series B
- SGInnovate (https://capitalatlas.ai/funds/sginnovate) — Series B
- AC Ventures — Series B
- Brama One Ventures — Series B
- Looking Glass Capital (https://capitalatlas.ai/funds/looking-glass-capital) — Series B
- Dexa International (https://capitalatlas.ai/funds/dexa-international) — Series B